Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (141-150 of 210) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERsMelody Cobleigh, Denise A Yardley, Adam M Brufsky, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Clinical and Translational Science|February 8, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) TrialD Max Smith, Rut Beyene, Paul Kolm, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Pageof 21

Showing results (141-150 of 210) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERsMelody Cobleigh, Denise A Yardley, Adam M Brufsky, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Clinical and Translational Science|February 8, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) TrialD Max Smith, Rut Beyene, Paul Kolm, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Pageof 21